CARsgen advances CAR T-cell therapies with breakthrough designation for satri-cel and first dose of KJ-C2219
CARsgen Therapeutics Holdings Limited has taken significant strides in the field of CAR T-cell therapy with two major developments in its pipeline. The company’s lead ... Read More
CARsgen Therapeutics completes enrollment in Phase II trial of Satri-cel for advanced gastric cancer
CARsgen Therapeutics Holdings Limited, a prominent player in the field of CAR T-cell therapies, has announced the successful completion of patient enrollment for its pivotal ... Read More